Neoadjuvant therapy for high-risk kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new treatment given before surgery for kidney cancer that is at high risk of coming back. The goal is to see if the treatment shrinks the tumor or improves surgery outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have been diagnosed with clear cell kidney cancer (the most common type) that is localized or locally advanced but has not spread to distant organs.
- Your cancer is considered high risk based on specific features like tumor size, grade, or lymph node involvement.
- You have not been treated with an immune checkpoint inhibitor (a type of immunotherapy) before.
- You are healthy enough for surgery and plan to receive this treatment before your surgery.
- Your organ function (heart, liver, kidneys, blood counts) is within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy and targeted drugs (called IO/TKI) given before and after surgery for clear cell renal cell carcinoma (a type of kidney cancer). The goal is to shrink tumors and improve survival outcomes.
This trial tests a new drug combination given before surgery for kidney cancer that is early stage but hard to operate on. The goal is to shrink the tumor and make surgery easier.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus either lenvatinib or axitinib for people with advanced clear cell kidney cancer that continued to grow after the first treatment. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two immunotherapy drugs (cemiplimab and fianlimab) given before surgery for high-risk kidney cancer that has not spread. The goal is to see if the drugs can help reduce the risk of the cancer coming back or spreading in the future.
This trial tests a combination of three medicines—pembrolizumab (a drug that helps your immune system fight cancer), belzutifan, and lenvatinib (drugs that slow tumor growth)—in patients with early-stage kidney cancer who are candidates for surgery. The goal is to see if this combination can improve outcomes before or alongside surgery.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
Hear when a new Urologic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.